EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission approved Amgen's IMDYLLTRA for extensive-stage small cell lung cancer based on Phase 3 DeLLphi-304 trial results showing 40% reduction in mortality risk versus chemotherapy.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
European Commission approval for IMDYLLTRA for extensive-stage small cell lung cancer
Importance:8/10
Sentiment:
0.85
regulatory approvalEuropean Commissiononcologysmall cell lung cancerPhase 3 data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 5:35 PM